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Abstract
Background: According to international guidelines [European Association for the Study of the Liver
(EASL) and the American Association for the Study of Liver Diseases (AASLD)], portal hypertension
(PHTN) is considered a contraindication for liver resection for hepatocellular carcinoma (HCC), and
patients should be referred for other treatments. However, this statement remains controversial. The aim
of this study was to elucidate surgical outcomes of minor hepatectomies in patients with PHTN (defined
by the presence of esophageal varices or a platelet count of <100 000 in association with splenomegaly)
and well-compensated liver disease.
Methods: Between 1997 and 2012, a total of 223 cirrhotic patients [stage A according to the Barcelona
Clinic Liver Cancer (BCLC) classification] were eligible for this analysis and were divided into two groups
according to the presence (n = 63) or absence (n = 160) of PHTN. The demographic data were comparable
in the two patient groups.
Results: Operative mortality was not different (only one patient died in the PHTN group). However,
patients with PHTN had higher liver-related morbidity (29% versus 14%; P = 0.009), without differences
in hospital stay (8.8 versus 9.8 days, respectively). The PHTN group showed a worse survival rate only if
biochemical signs of liver decompensation existed. Multivariate analysis identified albumin levels as an
independent predictive factor for survival.
Conclusions: PHTN should not be considered an absolute contraindication to a hepatectomy in cir-
rhotic patients. Patients with PHTN have short- and long-term results similar to patients with normal portal
pressure. A limited hepatic resection for early-stage tumours is an option for Child–Pugh class A5 patients
with PHTN.
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Introduction
In 1996, the Barcelona group demonstrated the presence of clini-
cally significant portal hypertension (PHTN), defined as a hepatic
venous pressure gradient (HVPG)  10 mmHg, to be the most
powerful predictor of post-operative liver decompensation and, in
a subsequent (1999) publication, of poor long-term outcome in
Child–Pugh A cirrhotic patients submitted to hepatic resection
(HR).1,2 However, measurement of HVPG is invasive and requires
technical expertise, whereas other clinical parameters are more
easily evaluated.3 Indeed, the presence of oesophageal varices as
determined by endoscopy or significant splenomegaly (major
diameter >12 cm) with a platelet count of <100 000/mm3 are
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considered surrogate markers of clinically significant PHTN,
regardless of portal pressure measurements.4 As a consequence of
these studies, the European Association for the Study of the Liver
(EASL) and American Association for the Study of Liver Diseases
(AASLD) guidelines consider PHTN to be a relative contraindi-
cation to HR because of the high risk of post-operative liver
decompensation.4,5
The literature is conflicting on the prognostic role of PHTN in
patients undergoing HR, as well as other important factors (e.g.
the degree of liver decompensation or type of HR) that seem to
influence the overall survival.6–11 The aims of this study were to
assess the results of HR in cirrhotic patients with HCC with or
without clinically significant PHTN, and the relationship in terms
of survival between liver function parameters and the presence of
clinical PHTN.
Patients and methods
Prospective databases (459 patients submitted to HR for HCC)
from two institutions (San Paolo Hospital, Milan, Italy and
Hopital Henri Mondor, Creteil, Paris) between February 1997 and
May 2012 were analysed. All patients referred to the Italian Centre
with the diagnosis of HCC were assessed for disease staging with
a pre-established protocol until 2000;12,13 it was then updated
according to the Barcelona Clinic Liver Cancer (BCLC) criteria.14
In Creteil, a similar algorithm has been used:15 selection criteria
for HR in patients with transplantable HCC included a solitary
tumour <5 cm, chronic hepatitis or Child’s class A cirrhosis, no
oesophageal varices and a platelet count 100 ¥ 109/l for major
HR and varices <grade 2 for minor HR, and an estimated remnant
liver volume >50%. Until 1998, all HR were performed through a
subcostal incision. Since 1998, the laparoscopic approach has been
used in selected patients for limited resection of peripheral HCC
<5 cm located in segments 2 to 6.
All patients were discussed at a weekly multidisciplinary
meeting at which surgeons, hepatologists and radiologists
exchanged opinions. The diagnosis and staging of HCC was based
on the appropriate imaging studies including triple-phase
computed tomography (CT) and/or magnetic resonance (MR)
according to the Barcelona-2000 EASL Conference, and histologi-
cal assessment when required.16 Eligibility for liver transplantation
[according to age, aetiology, Child–Pugh and model for end-stage
liver disease (MELD) score] or HR was evaluated. Unlike the
BCLC treatment protocol,12,13 in the time interval of this study, we
did not consider nodule size and number as absolute exclusion
criteria from surgical treatment. If no resection options were fea-
sible, patients were considered for laparoscopic or percutaneous
interstitial therapy, the latter for patients at higher surgical risk.
Transarterial chemoembolization was considered when patients
could not otherwise be treated by surgery or ablation.
In this cohort analysis, the residual liver function was evaluated
using the Child–Pugh classification17 and MELD.18 Upon referral,
laboratory tests including complete blood cell count, coagulation
profile, liver functions, plasma levels of alpha-fetoprotein (AFP)
and a chest X-ray were performed.
Patients were included in the present cohort analysis if they
fulfilled all of the following criteria on presentation: no previous
HR for HCC, a single lesion and tumour size less than 5 cm,
Child–Pugh class A and BCLC stage classes A1 to A3. Patient
characteristics and follow-up were recorded in a dedicated
database.
The presence of pre-operative portal hypertension1,4,5 was
evaluated retrospectively until 2000; from 2001, a clinical evalua-
tion has been used and portal hypertension was arbitrarily defined
as oesophageal varices detected by endoscopy or a splenomegaly
(major diameter >12 cm) with a platelet count <100 000/mm3,
according to the BCLC group criteria.4,5 Direct measurement of
venous pressure was not performed routinely in the current series,
All surgical procedures included intra-operative ultrasonogra-
phy (IOUS) examinations with intra-operative or laparoscopic
probes equipped with a multi-frequency linear-array transducer.
A laparotomy was performed using a standardized technique.13,15
Laparoscopic HR was the first choice in patients with HCC lesions
limited to the left lateral section of the liver or segments IVB, V
andVI.19–21 The specimens were evaluated histologically according
to Ishak et al.22 for fibrosis stage (0–6). Tumour grade was assessed
using the system outlined by Edmondson and Steiner,23 and was
based on the area showing the highest grade.24
Liver US and CT (and/or MRI) were performed within 3
months of treatment to assess the response to HR. Patients were
further followed locally by an expert hepatobiliary team every 6
months. Physical examination, liver function tests, serum AFP
level, liver US (twice a year) and CT (twice a year) were included.
Statistical analysis
The primary outcome was overall survival. Liver decompensation
was defined by the presence of ascites, acute encephalopathy
and/or jaundice (bilirubin level more than 3 mg/dl on postopera-
tive biochemical examinations). The follow-up time was defined
as the number of months from surgical treatment of HCC to
death, or last contact with the patient.
Comparison of continuous variables between and within
groups was performed using the Mann-Whitney U-test and Wil-
coxon’s matched pairs test. Continuous variables were also com-
pared by one-way analysis of variance (ANOVA) for normally
distributed variables between staging groups. Comparison of pro-
portions was performed with Fisher’s exact probability test. Bon-
ferroni’s correction for multiple comparisons was applied. Data
following a normal distribution were expressed as mean stand-
ard deviation; if non-parametric, median and range were
reported.
The univariate association of each parameter with survival rates
was estimated by comparing actuarial curves according to the
Kaplan–Meier product-limit method and log-rank test, which
more accurately characterizes the final outcome. The test trend of
the survivor function across the ordered groups was also calcu-
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lated: a relative hazard using the Cox regression-based test was
used to evaluate the weight of each subgroup in determining
significance.
Initial evaluation and subsequent follow-up data were collected
in a dedicated database (FileMaker Pro for Macintosh; FileMaker
Inc., Santa Clara, CA, USA) and subsequently analysed (Inter-
cooled Stata 10.0 for Macintosh, Stata Corp., College Station, TX,
USA).
The study was approved by the both hospitals’ Ethics Commit-
tees, and written informed consent for recording and analysis of
data were obtained from all patients.
Results
On the basis of inclusion criteria, 223 (48.6%) out of 459 patients
were included in this analysis: 160 (71.7%) patients were included
in a group without portal hypertension (no PHTN) whereas the
other 63 (28.3%) patients comprised the portal hypertension
(PHTN) group. In this group, 48 (76%) patients had oesophageal
varices detected by endoscopy (only 5 patients with F2 esophageal
varices) whereas the remaining 15 (24%) patients had indirect
signs of portal hypertension as previously defined. Direct meas-
urement of HVPG was performed in only 21 out of 223 patients.
Differences in characteristics of patients with PHTN and those
without PHTN are shown in Table 1. In particular, patients with
PHTN had more evident signs of liver dysfunction even if all
patients were classified as liver function in Child–Pugh A class:
they had lower serum albumin levels, higher total bilirubin levels,
higher INR (International Normalized Ratio) values resulting in
higher MELD scores and degree of fibrosis; conversely, they had
similar tumour diameter and AFP levels. Regarding fibrosis, Fig. 1
shows that 90% of PHTN patients had severe fibrosis (grade 6).
Table 2 shows intra-operative findings: patients with PHTN
underwent a lower rate of HR of 2 segments (17% versus 31%;
P = 0.038), whereas no differences were found regarding the other
parameters including the number of patients transfused (11%
versus 5.6%; P = NS).
During the immediate post-operative period, signs of liver
decompensation (the presence of ascites, encephalopathy and
bilirubin levels more than 3 mg/dl) were observed more fre-
quently in the PHTN group without influencing post-operative
hospital stay (Table 3): in fact, 16 out of 18 complicated patients in
the PHTN group (89%) and 18 out of 22 complicated patients in
the no-PHTN group (82%) had class I-II complications according
to Clavien.25 One patient died in the PHTN group as a result of
liver failure resulting in a 30-day mortality rate of 0.5% (no sta-
tistical difference with the no-PHTN group which had no mor-
tality). Also no statistical differences were found for 90-days
mortality: 3 (2%) patients in the no-PHTN group and 4 (6%)
patients in the PHTN group died (P = NS).
Table 1 Baseline characteristics of patients submitted to hepatic resection for hepatocellular carcinoma (HCC) with portal hypertension
(PHTN) or without portal hypertension (no PHTN)
Preoperative data 160 no-PHTN P 63 PHTN
Gender M/F 112/48
70%/30%
NS 45/18
71%/29%
Age (years) 66.8  9.6 NS 65.3  9.5
Aetiology (HCV, HBV or other) 91; 29; 40
57%; 18%; 25%
NS 44; 9; 10
70%; 14%; 16%
Liver cirrhosis 153 (96%) NS 63 (100%)
Child–Pugh class A 100% NS 100%
MELD 7.9  1.4 0.001 9.5 + 2.8
BCLC (A1; A2; A3) 160/0/0 0.001 0/37/26
Varices (F0) 0% 0.001 48 (76%)
Fibrosis (Ishak) 5.1  1.2 0.001 5.9  0.4
Bilirubin level (mg/dl) 0.80  0.36 0.001 1.39  1.55
Abnormal bilirubin (>1 mg/dl) 28 (19%) 0.001 36 (57%)
Albumin level (g/dl) 4.13  0.50 0.001 3.71  0.49
Abnormal albumin (<3.5 g/dl) 12 (9%) 0.001 21 (36%)
Prothrombin time (INR) 1.09  0.10 0.001 1.18  0.12
Abnormal INR (> 1.2) 7 (7%) 0.001 19 (36%)
HCC Diameter (mm) 28.3  10.9 NS 28.5  11.1
Edmondson–Steiner's classification (I-II; III-IV) 143; 9 (94%; 6%) NS 53; 6 (90%; 10%)
Vascular invasion (present) 49 (32%) NS 14 (23%)
AFP > 20ng/dl 50 (31%) NS 19 (30%)
MELD, model for end-stage liver disease; BCLC, Barcelona Clinic Liver Cancer; INR, international normalized ratio; HCC, hepatocellular carcinoma.
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The median follow-up period after HR was 25 months (range:
1–170). Long-term overall survival (Fig. 1) was poorer in the
PHTN group than in the no-PHTN group (3-/5-year: 66%/48%
versus 80%/65%, respectively; P = 0.024). However, among
patients with BCLC stage classification from A1 to A3 (introduc-
ing bilirubin into the univariate analysis) (Fig. 2a), the 3-/5-year
overall survival rates were, respectively, 77%/65% for the BCLCA1
class (no-PHTN), 70%/50% for the BCLC A2 class (PHTN with
normal bilirubin) and 58%/46% for the BCLC A3 class (PHTN
with abnormal bilirubin) (P = 0.070). The crude differences in
overall survivals were significant for comparisons between the
BCLC A1 and A3 groups (P = 0.021), but not between the BCLC
A1 and A2 and BCLCA2 and A3 groups (P =NS). Introducing the
albumin value into the univariate analysis (Fig. 2b), the 3-/5-year
overall survival rates were, respectively, 80%/65% in the
no-PHTN group, 70%/70% in the PHTN group with normal
albumin and 56%/22% in the PHTN group with abnormal
albumin (P = 0.001). Finally, introducing the INR value in to the
univariate analysis (Fig. 2c), the 3-/5-year overall survival rates
were, respectively, 80%/65% in the no-PHTN group, 69%/50% in
the PHTN group with normal INR and 57%/43% in the PHTN
group with an abnormal INR (P = 0.010). Among patients with
Child–Pugh stage A5 andA6 (Fig. 3), the 3-/5-year overall survival
rates were, respectively, 80%/65% in the no-PHTN group (with
Child–Pugh A5 or A6 class), 75%/75% in the PHTN group with
Child–Pugh A5 and 53%/24% in the PHTN group with Child–
Pugh A6 (P = 0.006).
Multivariate analysis with Cox’s regression confirmed that only
the albumin was related to survival with a hazard ratio of 2.20
(P = 0.028), whereas PHTN, characteristics of tumour and type of
HR were not related to survival (Table 4).
HCC recurrences were more frequent in the no PTHN group
(54%) than in PTHN group (37%; P = 0.020).
Discussion
PHTN in cirrhotic patients is considered a relative contraindica-
tion for HR according to EASL/AASLD guidelines. Bruix et al.1
analysed the outcome of 29 Child–Pugh class A patients with a
HVPG greater than 10 mmHg and observed a higher likelihood of
post-operative hepatic decompensation in these patients com-
pared with those without PHTN. In a subsequent publication,2 the
same authors confirmed that PHTN and serum bilirubin levels
were the independent prognostic factors affecting overall survival
after HR.
However, these results have not been confirmed by other
studies: in fact, recent Italian and Japanese studies have
reported contradictory results.6–11 These studies demonstrated
that cirrhotic patients with both clinically significant PHTN
and well-preserved liver function (evaluated by Child–Pugh clas-
sification or ICGR 15 value or MELD score) had similar short-
and long-term outcomes compared with patients without
PHTN, above all if resection of two or less segments were
performed.
Therefore, the prognostic relevance of clinically significant
PHTN after HR in patients with HCC is still a matter for debate.
Furthermore, two recent articles26,27 suggested that an increased
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Figure 1 Overall survival curves of the whole study population of 223
cirrhotic patients undergoing a hepatic resection (HR) for hepato-
cellular carcinoma (HCC) with the portal hypertension (PHTN) or
without PHTN (P = 0.024)
Table 2 Intra-operative findings
160 no-PHTN P 63 PHTN
HR > 2 segments 50 (31%) 0.038 11 (17%)
Laparoscopic approach 56 (35%) NS 26 (41%)
Operation time (min) 196  64 NS 189  69
Pringle manoeuver 88 (55%) NS 31 (49%)
Pringle timing (min) 30.5  26 NS 30.2  21
Intra-operative bleeding (ml) 292  262 NS 340  340
HR, hepatic resection; PHTN, portal hypertension, NS, not significant.
Table 3 Post-operative results
160 no-PHTN P 63 PHTN
Post-operative mortality 0 NS 1 (0.5%)
Total number of blood
transfusions
34 NS 14
Patients transfused 4 (5.6%) NS 7 (11%)
Liver decompensation 22 (14%) 0.009 18 (29%)
Ascitesa 18 (11%) 0.035 14 (22%)
Encephalopathya 4 (3%) NS 5 (8%)
Jaundicea 2 (1%) NS 3 (5%)
Post-operative hospital stay
(days)
9.8  7.5 NS 8.8  5.5
PHTN, portal hypertension, NS, not significant.
aMore than one complication for each patient.
HPB 81
HPB 2013, 15, 78–84 © 2012 International Hepato-Pancreato-Biliary Association
HVPG was associated with post-operative liver failure and mor-
tality after HR in patients with HCC and liver cirrhosis, whereas
indirect criteria of clinically significant PHTN were not.
The current study confirmed that the presence of clinically
significant PHTN (even if evaluated only by clinical criteria) could
influence the post-operative course of cirrhotic patients submit-
ted to HR. However, if stringent pre-operative selection criteria
are met (i.e. Child–Pugh class A patients undergoing limited HR,
with a laparoscopic approach if indicated) and limited HR are
performed (less than 2 segments in 31% of the no PHTN group
and 17% of the PHTN group), the post-operative mortality rate is
very low (1.59% in the PHTN group and 0.45% in all patients).
Furthermore, even if post-operative complications as a result of
temporary hepatic failure weremore frequent in the PHTN group,
they were slight and transient as evidenced by Clavien’s classified
complications25 and the similar post-operative hospital stay in the
two groups.
As regards the long-term outcomes, the data from the present
study confirm the recent publications in the literature.6–11 If
patients with and without PHTN irrespective of any sign of liver
decompensation are analysed, long-term survival was significantly
lower in patients with clinically significant PHTN (P = 0.024).
However, including laboratory parameters in the analysis of long-
term survival (i.e. albumin, bilirubin and INR), it is possible to
identify a subgroup of patients in which the association of clini-
cally significant PHTN with an abnormal biochemical parameter
has prognostic relevance after HR. In other words, patients with
clinically significant PHTN and Child–Pugh class A6 showed
worse long-term survival after HR than patients without clinical
PHTN or with PHTN and normal liver function parameters
(Child–Pugh A5).
Probably, clinically significant PHTN influenced the outcome
of patients submitted to HR only if some degree of hepatic
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Figure 2 Survival curves according to the portal hypertension
(PHTN) and biochemical parameters: (a) Barcelona Clinic Liver
Cancer (BCLC) A1 class (no-PHTN) versus BCLC A2 class (PHTN
and normal bilirubin) versus BCLC A3 class (PHTN and abnormal
bilirubin); (b) no-PHTN vesus PHTN and normal albumin versus
PHTN and abnormal albumin; (c) no-PHTN versus PHTN and normal
international normalized ratio (INR) versus PHTN and an abnormal
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compensation started (Child–Pugh A6), even if methods of liver
function evaluation seemed to show good hepatic reserve (Child–
Pugh A class). In fact, as suggested by other publications,26,28
PHTN is well correlated with the degree of liver fibrosis and in the
present series, 90.5% of patients with PHTN had severe fibrosis
(grade 6 according Ishak classification) in comparison with
patients without PHTN (56.5%; P = 0.004) while no patient with
PHTN had mild fibrosis (grade 0–3).
In conclusion, the current study indicates that cirrhotic
patients with HCC and hepatic compensation (Child–Pugh A
class) being considered for HR should be evaluated not only for
the presence of clinically significant PHTN, but for biochemical
parameters as well: patients with clinically relevant PHTN and
abnormal biochemical parameters (e.g. bilirubin, albumin or
INR) should be referred for other treatment options such as
radiofrequency ablation and/or OLT. Patients without PHTN or
with clinically significant PHTN and preserved liver function
(Child–Pugh A5 class) can undergo HR with the best chances of
long-term survival without post-operative impairment of liver
function. If possible, limited HR (less than 2 segments) and a
laparoscopic approach should be pursued. If a major HR is nec-
essary, non-surgical therapies should be pursued even if it is
known that patients with clinically significant PHTN have a
negative prognosis irrespective of the treatment choice, or liver
transplantation should be considered the only valid therapeutic
strategy.
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